Login to Your Account



XOMA: Short Perindopril Data May 'Coveram' for NDA Filing

By Randy Osborne
Staff Writer

Wednesday, November 21, 2012
in_the_clinic.jpg

Six weeks of positive results in Phase III trials with the fixed-dose combination (FDC) of perindopril arginine with amlodipine besylate for high blood pressure should be enough – when packaged with data from overseas, where it's marketed already as Coveram – to justify a new drug application (NDA), said XOMA Corp.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription